Provided by Tiger Trade Technology Pte. Ltd.

Pacira Pharmaceuticals

26.29
+0.56002.18%
Post-market: 26.290.00000.00%17:56 EST
Volume:1.13M
Turnover:29.41M
Market Cap:1.13B
PE:55.78
High:26.46
Open:25.74
Low:25.17
Close:25.73
52wk High:27.64
52wk Low:18.17
Shares:43.02M
Float Shares:37.84M
Volume Ratio:1.36
T/O Rate:2.97%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.4713
EPS(LYR):-2.1529
ROE:2.90%
ROA:2.89%
PB:1.56
PE(LYR):-12.21

Loading ...

Pacira Biosciences CFO Shawn Cross Reports Disposal of Common Shares

Reuters
·
Dec 12

Pacira BioSciences (PCRX): Valuation Check After New Iovera Clinical Data and Smart Tip FDA Clearance

Simply Wall St.
·
Dec 11

Pacira BioSciences Initiated at Equal-Weight by Barclays

Dow Jones
·
Dec 10

BRIEF-Pacira Biosciences Reports Inducement Grants Under Nasdaq Listing Rule

Reuters
·
Dec 03

Pacira Biosciences Grants Inducement Awards to New Employees

Reuters
·
Dec 03

Pacira Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Dec 03

Pacira Biosciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With Iovera° Compared to Radiofrequency Ablation in Chronic Low Back Pain

THOMSON REUTERS
·
Dec 02

Pacira Biosciences Study Finds Iovera° Superior to Radiofrequency Ablation for Chronic Low Back Pain

Reuters
·
Dec 02

Pacira Biosciences: Seeks Injunction to Prevent Manufacture, Use, Sale of Generic Products Described in Each Co's Anda Filed With U.S. FDA

THOMSON REUTERS
·
Nov 27

Pacira Biosciences Files Exparel® Patent Infringement Lawsuits Against the Whiteoak Group and Qilu Pharmaceutical

THOMSON REUTERS
·
Nov 27

Pacira Biosciences: Lawsuits Triggered 30-Month Stay of Final FDA Approval of Andas Under Hatch Waxman Act

THOMSON REUTERS
·
Nov 27

Pacira BioSciences Files Patent Infringement Lawsuits to Protect EXPAREL® Against Generic Competitors

Reuters
·
Nov 27

Pacira Biosciences Chief Medical Officer Jonathan Slonin Reports Sale of Common Shares

Reuters
·
Nov 20

Pacira BioSciences Coverage Assumed by HC Wainwright & Co. at Buy

Dow Jones
·
Nov 17

Pacira Biosciences Inc : H.c. Wainwright Assumes Coverage With Buy Rating; Target Price $38

THOMSON REUTERS
·
Nov 17

Bitdeer, Pacira BioSciences, Garrett Motion, and More Stocks See Action From Activist Investors -- Barrons.com

Dow Jones
·
Nov 15

Pacira Biosciences CFO Shawn Cross Reports Disposal of Common Shares

Reuters
·
Nov 14

Pacira BioSciences to Join Jefferies London Healthcare Conference

Reuters
·
Nov 11

BRIEF-Doma Perpetual Urges Pacira Biosciences To Immediately Explore Sale Of The Business

Reuters
·
Nov 11

Doma Perpetual Sends Letter Calling for the Board of Directors of Pacira Biosciences, Inc. to Immediately Explore a Sale of the Business

THOMSON REUTERS
·
Nov 11